NCT01640535View on ClinicalTrials.gov

Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

283

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Perennial Allergic Rhinitis
Interventions
DRUG

Montelukast + Levocetirizine

Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)

DRUG

Levocetirizine

Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)

DRUG

Montelukast

Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)

Trial Locations (1)

420-767

Soonchunhyang University Bucheon Hospital, Bucheon-si

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01640535 - Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients | Biotech Hunter | Biotech Hunter